Suppr超能文献

小肾肿瘤的治疗管理:美国临床肿瘤学会临床实践指南。

Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.

机构信息

Antonio Finelli and Michael A.S. Jewett, Princess Margaret Cancer Center; Andrew Evans, University Health Network, Toronto; Bobby Shayegan, St Joseph Hospital, Hamilton, Ontario, Canada; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria; Mitchell Rosner, University of Virginia School of Medicine, Charlottesville, VA; Bill Bro, Kidney Cancer Association; Scott Eggener, University of Chicago, Chicago, IL; Jeremy Durack, Sheron Latcha, and Paul Russo, Memorial Sloan Kettering Cancer Center; William Huang, New York University Langone Medical Center, New York, NY; Inderbir Gill, University of Southern California, Los Angeles, CA; David Graham, Levine Cancer Institute, Charlotte, NC; William Lowrance, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; R. Houston Thompson, Mayo Clinic, Rochester, MN; and Robert Uzzo, Fox Chase Cancer Center, Philadelphia, PA.

出版信息

J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17.

Abstract

Purpose To provide recommendations for the management options for patients with small renal masses (SRMs). Methods By using a literature search and prospectively defined study selection, we sought systematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational studies, and retrospective studies published from 2000 through 2015. Outcomes included recurrence-free survival, disease-specific survival, and overall survival. Results Eighty-three studies, including 20 systematic reviews and 63 primary studies, met the eligibility criteria and form the evidentiary basis for the guideline recommendations. Recommendations On the basis of tumor-specific findings and competing risks of mortality, all patients with an SRM should be considered for a biopsy when the results may alter management. Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy. Partial nephrectomy (PN) for SRMs is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach. Percutaneous thermal ablation should be considered an option if complete ablation can reliably be achieved. Radical nephrectomy for SRMs should only be reserved for patients who possess a tumor of significant complexity that is not amenable to PN or for whom PN may result in unacceptable morbidity even when performed at centers with expertise. Referral to a nephrologist should be considered if chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73 m) or progressive chronic kidney disease occurs after treatment, especially if associated with proteinuria.

摘要

目的 为小肾肿瘤 (SRM) 患者的管理选项提供建议。

方法 通过文献检索和前瞻性定义的研究选择,我们寻求了 2000 年至 2015 年期间发表的系统评价、荟萃分析、随机临床试验、前瞻性对照观察研究和回顾性研究。结果包括无复发生存率、疾病特异性生存率和总生存率。

结果 83 项研究,包括 20 项系统评价和 63 项主要研究,符合入选标准,构成指南建议的证据基础。

建议 根据肿瘤特异性发现和死亡的竞争风险,所有 SRM 患者都应考虑进行活检,因为结果可能改变治疗方案。对于存在严重合并症和预期寿命有限的患者,主动监测应作为初始管理选择。对于需要干预且肿瘤适合这种方法的所有患者,应提供部分肾切除术 (PN) 作为治疗 SRM 的标准治疗方法。对于可以可靠实现完全消融的患者,应考虑采用经皮热消融。对于不适合 PN 或即使在有专业知识的中心进行 PN 也可能导致不可接受的发病率的肿瘤复杂性较大的患者,仅应保留根治性肾切除术作为治疗选择。如果治疗后发生慢性肾脏病 (估计肾小球滤过率 < 45 mL/min/1.73 m) 或慢性肾脏病进展,应考虑转介给肾病专家,特别是如果伴有蛋白尿。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验